1. Engraft beneficial commensal bacterial species in the gastrointestinal tract of patients with profound dysbiosis and reduced concentrations of microbiota-derived metabolites.
2. Re-establish commensal bacterial species and fecal metabolites that are associated with resistance to infection, immunomodulation and strengthening of mucosal epithelial barrier function in the lower gastrointestinal tract.
3. Reduce density of intestinal colonization with antibiotic-resistant pathobionts such as Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli.
4. Reduce the incidence and/or progression of spontaneous bacterial peritonitis, bacterial bloodstream infections and progression of respiratory viral and bacterial infections. Less...